SMT201400155B - Composizioni farmaceutiche comprendenti derivati di 2-osso-1-pirrolidina - Google Patents

Composizioni farmaceutiche comprendenti derivati di 2-osso-1-pirrolidina

Info

Publication number
SMT201400155B
SMT201400155B SM201400155T SM201400155T SMT201400155B SM T201400155 B SMT201400155 B SM T201400155B SM 201400155 T SM201400155 T SM 201400155T SM 201400155 T SM201400155 T SM 201400155T SM T201400155 B SMT201400155 B SM T201400155B
Authority
SM
San Marino
Prior art keywords
pyrrolidine
oxo
derivatives
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
SM201400155T
Other languages
English (en)
Inventor
Serge Cuypers
Monique Berwaer
Domenico Fanara
Valery Barillaro
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of SMT201400155B publication Critical patent/SMT201400155B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201400155T 2009-01-29 2014-10-23 Composizioni farmaceutiche comprendenti derivati di 2-osso-1-pirrolidina SMT201400155B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09100083 2009-01-29
PCT/EP2010/050892 WO2010094535A1 (en) 2009-01-29 2010-01-27 Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
EP10701245.2A EP2391349B1 (en) 2009-01-29 2010-01-27 Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
SMT201400155B true SMT201400155B (it) 2015-01-15

Family

ID=40622206

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400155T SMT201400155B (it) 2009-01-29 2014-10-23 Composizioni farmaceutiche comprendenti derivati di 2-osso-1-pirrolidina

Country Status (22)

Country Link
US (2) US20120108464A1 (it)
EP (1) EP2391349B1 (it)
JP (1) JP5576401B2 (it)
KR (1) KR101640164B1 (it)
CN (2) CN104083328B (it)
AU (1) AU2010215646B2 (it)
BR (1) BRPI1007161B1 (it)
CA (1) CA2747395C (it)
CY (1) CY1115673T1 (it)
DK (1) DK2391349T3 (it)
EA (1) EA022057B1 (it)
ES (1) ES2511047T3 (it)
HR (1) HRP20141006T1 (it)
IL (1) IL213545A (it)
ME (1) ME01927B (it)
MX (1) MX2011007267A (it)
PL (1) PL2391349T3 (it)
PT (1) PT2391349E (it)
RS (1) RS53554B1 (it)
SI (1) SI2391349T1 (it)
SM (1) SMT201400155B (it)
WO (1) WO2010094535A1 (it)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010209790B2 (en) * 2009-01-29 2014-01-16 Ucb Pharma, S.A. Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
CN104800176A (zh) * 2015-04-23 2015-07-29 广东赛烽医药科技有限公司 一种布瓦西坦口崩片及其制备方法
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US20190125725A1 (en) * 2016-05-12 2019-05-02 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
SG11202001436YA (en) 2017-08-18 2020-03-30 Abbvie Inc Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
TW201912157A (zh) * 2017-08-18 2019-04-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物
CN109833300A (zh) * 2017-11-28 2019-06-04 浙江京新药业股份有限公司 一种抗癫痫药物口服组合物及其制备方法
US11690854B2 (en) 2018-04-19 2023-07-04 Abbvie Inc. Methods of treating heavy menstrual bleeding
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
CN113288872A (zh) * 2020-02-21 2021-08-24 广东东阳光药业有限公司 一种2-吡咯烷酮衍生物的组合物及其制备方法
CN112933059A (zh) * 2021-03-25 2021-06-11 浙江昂利康制药股份有限公司 一种布立西坦片剂的干法制粒工艺
CN115192572B (zh) * 2021-04-08 2023-09-19 成都同道慧宜生物医药科技有限公司 布立西坦药剂、其制备方法和应用
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用
EP4431086A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide
EP4491177A1 (en) 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. Film coated tablets of brivaracetam
EP4491176A1 (en) 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. A film coated tablet comprising brivaracetam
EP4527378A1 (en) 2023-09-22 2025-03-26 Sanovel Ilac Sanayi ve Ticaret A.S. A film coated tablet of brivaracetam

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
AP2003002900A0 (en) * 2001-05-01 2003-12-31 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition
JP2005298338A (ja) 2002-02-27 2005-10-27 Eisai Co Ltd 速崩壊性圧縮成形製剤
CN1186094C (zh) * 2002-07-01 2005-01-26 蔡海德 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法
US7799538B2 (en) * 2005-03-09 2010-09-21 Trustees Of Dartmouth College Method for identifying agents which modulate GTPase activity involved in insulin-stimulated GLUT4 translocation
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
PL1909764T3 (pl) * 2005-07-26 2015-03-31 Ucb Pharma Sa Kompozycje farmaceutyczne zawierające lewetyracetam i sposób ich wytwarzania
EP2041084B1 (en) 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
WO2008085927A2 (en) * 2007-01-05 2008-07-17 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of pain
AU2010209790B2 (en) * 2009-01-29 2014-01-16 Ucb Pharma, S.A. Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives

Also Published As

Publication number Publication date
CY1115673T1 (el) 2017-01-25
PL2391349T3 (pl) 2014-12-31
CN104083328A (zh) 2014-10-08
ES2511047T3 (es) 2014-10-22
ME01927B (me) 2015-05-20
DK2391349T3 (da) 2014-11-03
PT2391349E (pt) 2014-10-27
CN104083328B (zh) 2017-04-12
BRPI1007161B1 (pt) 2022-03-22
CN102292071A (zh) 2011-12-21
HK1161988A1 (zh) 2012-08-17
US10729653B2 (en) 2020-08-04
HRP20141006T1 (hr) 2014-12-19
US20120108464A1 (en) 2012-05-03
CA2747395A1 (en) 2010-08-26
MX2011007267A (es) 2011-08-15
IL213545A0 (en) 2011-07-31
SI2391349T1 (sl) 2014-12-31
IL213545A (en) 2016-05-31
EA201101116A1 (ru) 2012-03-30
CN102292071B (zh) 2016-08-24
JP2012516302A (ja) 2012-07-19
HK1198287A1 (en) 2015-03-27
WO2010094535A1 (en) 2010-08-26
BRPI1007161A2 (pt) 2016-02-23
CA2747395C (en) 2015-01-13
AU2010215646A1 (en) 2011-08-04
EA022057B1 (ru) 2015-10-30
JP5576401B2 (ja) 2014-08-20
EP2391349B1 (en) 2014-07-23
KR20120008022A (ko) 2012-01-25
KR101640164B1 (ko) 2016-07-15
AU2010215646B2 (en) 2014-03-27
US20110281929A1 (en) 2011-11-17
RS53554B1 (sr) 2015-02-27
EP2391349A1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
SMT201500316B (it) Derivati di benzotiazolo come agenti anticancro
SMT201600338B (it) Formulazioni farmaceutiche comprendenti derivati di1-(beta-d- glucopiranosil)- 2-tienilmetilbenzene come inibitori di sglt
DK2395834T3 (da) Natriumnitrit-holdige farmaceutiske sammensætninger
BRPI1012539A2 (pt) composições farmacêuticas
HRP20161312T1 (hr) Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
LT3061445T (lt) Labai koncentruotos farmacinės kompozicijos
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
EP2451274A4 (en) Pharmaceutical compositions
DK3284467T3 (da) Nikotinholdige farmaceutiske sammensætninger
DK2498756T3 (da) Tabletformuleringer af neratinibmaleat
SMT201700095B (is) Composizioni farmaceutiche per inalazione
SMT201400069B (it) Formulazione farmaceutica
LT3222272T (lt) Farmacinė karbetocino kompozicija
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
BRPI1015939A2 (pt) composição farmacêutica
IT1394400B1 (it) Composizioni farmaceutiche
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
DK2408446T3 (da) Anvendelse af farmaceutiske sammensætninger, der indeholder mesembrenon
SMAP200900065A (it) Derivati ciclizzati come inibitori di eg-5
SMT201300067B (it) Applicazioni terapeutiche di derivati di chinazolindione
SMT201400080B (it) Derivati di pirazinoossazepina